BridgeMD
Comparison of 18F-Fluciclovine PET versus 18F-Fluoroethyltyrosine PET in patients with newly diagnosed cerebral gliomas, recurrent cerebral gliomas and brain metastases – an open label single centre single arm prospective basket trial
EU CTIS ID: 2023-507786-26-00
What this study is testing
Assessment of agreement on tumour size and tracer distribution in FET PET and FACBC PET in the examined patients.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patient is ≥ 18 years old.
- Patient is mentally and physically able to understand the significance and scope of the study and to comply with the study staff.
- Patient has decision-making capacity: capable of giving consent, insight, and information.
- Patient has signed a written informed consent form prior to participation in the study.
- Patient is referred to the Nuclear Medicine Clinic of the University Hospital Aachen for FET PET of the brain based on the prescription of the treating physicians.
- Patient has suspected glioma prior to biopsy or surgery. OR
You likely can't join if
- Patient is pregnant or breastfeeding.
- Patient is not willing to take adequately safe contraceptive measures.
- Patient is institutionalised due to official or court order.
- Patient is in a dependent relationship or employment relationship with the sponsor, investigator or his or her deputy.
- Patient has insufficiently controlled epilepsy.
- Patient is unable to lie still for 40 minutes.
See the full eligibility criteria
- Patient is ≥ 18 years old.
- Patient is mentally and physically able to understand the significance and scope of the study and to comply with the study staff.
- Patient has decision-making capacity: capable of giving consent, insight, and information.
- Patient has signed a written informed consent form prior to participation in the study.
- Patient is referred to the Nuclear Medicine Clinic of the University Hospital Aachen for FET PET of the brain based on the prescription of the treating physicians.
- Patient has suspected glioma prior to biopsy or surgery. OR
- Patient has suspected tumour recurrence after previous treatment for cerebral glioma or brain metastasis.
- Patient is pregnant or breastfeeding.
- Patient is not willing to take adequately safe contraceptive measures.
- Patient is institutionalised due to official or court order.
- Patient is in a dependent relationship or employment relationship with the sponsor, investigator or his or her deputy.
- Patient has insufficiently controlled epilepsy.
- Patient is unable to lie still for 40 minutes.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.